(Q46559649)

English

Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.

scientific article published on 27 February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

author name string

Hussein A Sheashaa

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Mohamed A Bakr

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Mohamed Ashraf Fouda

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Khalid F El-Dahshan

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Amany M Ismail

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Mohamed A Sobh

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Mohamed A Ghoneim

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

publication date

27 February 2007

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

International Urology and Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

39

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

317-319

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Banff 97 working classification of renal allograft pathology

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunosuppressive treatment and progression of histologic lesions in kidney allografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17333530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11255-006-9091-8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/17333530

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46559649&oldid=1398648927"